Skip to content
Screener

Xeris Biopharma Holdings, Inc. XERS Q3 2025 earnings

Reported November 6, 2025 · Before market open

Revenue$74.4MMiss by $11.6M
EPS$0.00Miss by $0.01
Revenue estimate$86.0M
EPS estimate$0.01

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$101.6M
EPS estimate$0.02

Financials

Q3 2025

Income statement

See full
Revenue$74.4M+37.1%
Gross profit$63.4M+55.8%
Operating income$6.7M+152%
Net income$621.0K+104%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$91.6M+54.6%
Total debt$257.7M-4.9%
Total equity-$861.0K+97.0%
Total assets$370.2M+15.3%

Cash flow

See full
Operating cash flow$18.4M+322%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.31B+211%
Enterprise value$1.48B+133%
P/S4.9×+2.7×

Profitability

See full
Gross margin84.6%+3.2pp
Operating margin3.1%+1.6pp
Net margin-5.9%-2.7pp

Returns & leverage

See full
Current ratio1.9×+0.1×

Segments

By product

See full
Recorlev$37.0M+109%
Gvoke$25.2M+9.6%
Keveyis$11.9M-2.1%
Royalty, contract and other revenue$317.0K-77.5%
Other product revenue-—

FAQ

When did Xeris Biopharma Holdings, Inc. report Q3 2025 earnings?
Xeris Biopharma Holdings, Inc. (XERS) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Xeris Biopharma Holdings, Inc.'s Q3 2025 revenue and EPS?
Xeris Biopharma Holdings, Inc. reported revenue of $74.4M and eps of $0.00 for Q3 2025.
Did Xeris Biopharma Holdings, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $86.0M by $11.6M. EPS missed the consensus estimate of $0.01 by $0.01.
How did Xeris Biopharma Holdings, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 37.1% from $54.3M a year earlier.
Where can I find Xeris Biopharma Holdings, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001867096-25-000156) and the 10-Q periodic report (0001867096-25-000159) directly on SEC EDGAR. The filing index links above go to sec.gov.